We estimate that 418 million disability-adjusted life years (DALYs) could be attributable to mental disorders in 2019 (16% of global DALYs)—a more than three-fold increase compared to conventional ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...